KALA BIO, Inc. (KALA) Earnings History
Net Loss13 years of earnings data (2013–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
KALA BIO, Inc. (KALA) Earnings Overview
As of June 22, 2026, KALA BIO, Inc. (KALA) reported trailing twelve-month net income of -$20M, reflecting +52.6% year-over-year growth. The company earned $-2.41 per diluted share over the past four quarters.
Looking at the long-term picture, KALA's historical earnings data spans multiple years. The company achieved its highest annual net income of -$11M in fiscal 2013.
KALA BIO, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including OCUL (-$290M net income, -513.2% margin), LNTH ($279M net income, 15.2% margin), HROW (-$15M net income, -1.9% margin), KALA has comparable earnings metrics. Compare KALA vs OCUL →
KALA Earnings vs Peers
Earnings metrics vs comparable public companies
KALA Historical Earnings Data (2013–2025)
13 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$27M | +29.9% | -$39M | $-3.31 | - | - |
| 2024 | -$39M | +8.7% | -$40M | $-6.98 | - | - |
| 2023 | -$42M | +5.9% | -$39M | $-17.35 | - | - |
| 2022 | -$45M | +68.6% | -$81M | $-29.48 | -1151.6% | -2090.3% |
| 2021 | -$143M | -36.7% | -$109M | $-109.35 | -1268.7% | -973.6% |
| 2020 | -$104M | -10.6% | -$96M | $-99.59 | -1639.8% | -1512.6% |
| 2019 | -$94M | -41.4% | -$88M | $-149.06 | -1553.3% | -1452.5% |
| 2018 | -$67M | -58.1% | -$65M | $-124.73 | - | - |
| 2017 | -$42M | -27.3% | -$40M | $-99.20 | - | - |
| 2016 | -$33M | -98.8% | -$33M | $-95.95 | - | - |
| 2015 | -$17M | +13.8% | -$16M | $-48.26 | -37071.1% | -35435.6% |
| 2014 | -$19M | -81.7% | -$18M | $-40.03 | -4255.2% | -3920.9% |
| 2013 | -$11M | - | -$11M | $-22.03 | -21306.0% | -22264.0% |
Download Data
Export KALA earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
13+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
KALA — Frequently Asked Questions
Quick answers to the most common questions about buying KALA stock.
What is KALA earnings per share (EPS)?
KALA trailing twelve-month (TTM) diluted EPS is $-2.41, reflecting +52.6% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2013 to 2025 is available in the table on this page.
What is KALA BIO, Inc.'s net income?
KALA BIO, Inc. (KALA) trailing twelve-month net income is $-20M as of 2025. Earnings grew +52.6% year-over-year.
Is KALA profitable?
KALA is not currently profitable on a TTM basis, reporting a net loss of $-20M. Net margin is N/A. Investors should monitor for a return to profitability.
What is KALA's earnings growth rate?
KALA compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2013 to 2025.
What are KALA's profit margins?
KALA BIO, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -279.2%.
Is KALA growing earnings?
Yes, KALA earnings are accelerating — EPS growth of +52.6% exceeds the 5-year CAGR of N/A. TTM net income reached $-20M. Earnings momentum is strengthening.
What was KALA's best earnings year?
KALA BIO, Inc.'s highest annual net income on record is $-11M, achieved in fiscal year 2013. Earnings history on this page spans 2013 to 2025 and includes all annual and quarterly figures.
What were KALA's earnings last quarter?
KALA's most recent reported quarter was Q1 2026. Net income was $-2M with diluted EPS of $-0.20. For a full breakdown of all quarters, see the quarterly earnings table on this page.